

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated October 25, 2022 (the “**Prospectus**”) issued by Giant Biogene Holding Co., Ltd (the “**Company**”).

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any securities of the Company. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or any other jurisdictions. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”), or any applicable state securities laws, and may not be offered, sold, pledged or transferred within the United States unless pursuant to an exemption from, or in a transaction that is not subject to, the registration requirements of the U.S. Securities Act. There will be no public offering of securities of the Company in the United States.



## **GIANT BIOGENE HOLDING CO., LTD**

*(An exempted company incorporated in the Cayman Islands with limited liability)*

**(Stock code: 2367)**

### **FULL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD**

#### **FULL EXERCISE OF THE OVER-ALLOTMENT OPTION**

We refer to the Prospectus and the allotment results announcement of the Company dated November 3, 2022. On November 25, 2022 (after trading hours), the Joint Global Coordinators (for themselves and on behalf of the International Underwriters) has fully exercised the Over-allotment Option in respect of an aggregate of 3,391,200 Shares (the “**Over-allotment Shares**”), representing approximately 15% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option.

Pursuant to the Stock Borrowing Agreement entered into between Goldman Sachs International (an affiliate of Goldman Sachs (Asia) L.L.C.) and Juzi Holding Co., Ltd, Goldman Sachs International has borrowed an aggregate of 3,391,200 Shares from Juzi Holding Co., Ltd to cover over-allocations in the International Offering. The Over-allotment Shares will be used to facilitate the return to Juzi Holding Co., Ltd of the borrowed Shares.

The Company will allot and issue the Over-allotment Shares at HK\$24.30 per Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, Hong Kong Stock Exchange trading fee of 0.005% and AFRC transaction levy of 0.00015%), being the International Offer Price.

### Approval of Listing

The Listing Committee of the Hong Kong Stock Exchange has granted the approval for the listing of and permission to deal in the Over-allotment Shares. Listing of and dealings in the Over-allotment Shares on the Main Board of the Hong Kong Stock Exchange will commence at 9:00 a.m. on November 30, 2022.

### Shareholding Structure of the Company upon the Full Exercise of the Over-allotment Option

The shareholding structure of the Company immediately before and after the completion of the allotment and issue of the Over-allotment Shares pursuant to the Over-allotment Option is as follows:

	Immediately before the allotment and issue of the Over-allotment Shares		Immediately after the allotment and issue of the Over-allotment Shares	
	Number of issued Shares	Approximate % of total issued share capital	Number of issued Shares	Approximate % of total issued share capital
Juzi Holding <sup>(1)</sup>	581,104,935	58.60%	581,104,935	58.40%
Healing Holding <sup>(1)</sup>	900,000	0.09%	900,000	0.09%
GBEBT Holding <sup>(1)</sup>	19,000,000	1.92%	19,000,000	1.91%
<b>Subtotal</b>	<b>601,004,935</b>	<b>60.61%</b>	<b>601,004,935</b>	<b>60.40%</b>
Public Shareholders	390,603,865	39.39%	393,995,065	39.60%
<b>Total<sup>(2)</sup></b>	<b>991,608,800</b>	<b>100.00%</b>	<b>995,000,000</b>	<b>100.00%</b>

Notes:

- (1) Dr. Fan, Mr. Yan, Juzi Holding, Refulgence Holding, Healing Holding and GBEBT Holding constitute a group of Controlling Shareholders upon completion of the Global Offering. For details, please see the section headed "Relationship with Our Controlling Shareholders" in the Prospectus.
- (2) Any discrepancies in the table between the totals and the sums of the amounts listed therein are due to rounding.

### Use of Proceeds

The Company will receive additional net proceeds of approximately HK\$77.9 million for the issue of the Over-allotment Shares, after deducting offering expenses payable by it in relation to the exercise of the Over-allotment Option. The Company intends to apply the additional net proceeds towards the same purposes as set out in the section headed "Future Plans and Use of Proceeds" in the Prospectus.

## STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company further announces that the stabilization period in connection with the Global Offering ended on November 27, 2022, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering.

Goldman Sachs (Asia) L.L.C., as the Stabilizing Manager, or any person acting for it during the stabilization period, has undertaken the following stabilizing actions:

- (1) over-allocations of an aggregate of 3,391,200 Shares in the International Offering, representing approximately 15% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option;
- (2) borrowing of an aggregate of 3,391,200 Shares from Juzi Holding Co., Ltd pursuant to the Stock Borrowing Agreement to cover over-allocations in the International Offering;
- (3) the full exercise of the Over-allotment Option by the Joint Global Coordinators (for themselves and on behalf of the International Underwriters) on November 25, 2022, in respect of an aggregate of 3,391,200 Shares, representing approximately 15% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, to facilitate the return to Juzi Holding Co., Ltd of the borrowed Shares under the Stock Borrowing Agreement which were used to cover over-allocations in the International Offering.

No purchase or sale of any Shares on the market for the purpose of price stabilization was made by the Stabilizing Manager during the stabilization period.

## PUBLIC FLOAT

Immediately after the end of the stabilization period, the Company will continue to comply with the minimum public float requirement under Rule 8.08(1)(a) of the Listing Rules.

By order of the Board  
**Giant Biogene Holding Co., Ltd**  
**YAN Jianya**  
*Chairman of the Board*

Hong Kong, Sunday, November 27, 2022

*As of the date of this announcement, the Board comprises Mr. Yan Jianya, Dr. Fan Daidi, Ms. Ye Juan and Ms. Fang Juan as executive Directors, Mr. Chen Jinhao as a non-executive Director, and Mr. Huang Jin, Mr. Shan Wenhua and Ms. Wong Sze Wing as independent non-executive Directors.*